AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3710742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate 200 mg I/ml
Number of subjects: 229
Study 3710742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 229
Study 3218859 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple intervention to teach interviewing skills
Number of subjects: 0
Study 31895796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon (Cinnamomum verum) 3 grams per day for 90 days
Number of subjects: 130
Study 31895796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 30833371 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 278
Study 30833371 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 278
Study 30833371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 28438923 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-clavulanate A/C formulation (90 mg amoxicillin/3.2 mg clavulanate/kg/day for 10 days)
Number of subjects: 112
Study 28438923 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-clavulanate A/C formulation (80 mg amoxicillin/2.85 mg clavulanate/kg/day for 10 days)
Number of subjects: 112
Study 28438923 — intervention group
Group type: COMPARATOR
Intervention: Standard A/C regimen (90 mg amoxicillin/6.4 mg clavulanate/kg/day)
Number of subjects: 112
Study 25557606 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Number of subjects: 75
Study 25557606 — intervention group
Group type: COMPARATOR
Intervention: No-stress protocol
Number of subjects: 75
Study 23020935 — intervention group
Group type: EXPERIMENTAL
Intervention: Child age, swimming lessons, home equipment
Number of subjects: 76
Study 23020935 — intervention group
Group type: EXPERIMENTAL
Intervention: Child age, sex, unstructured activity participation, MVPA%, parent confidence, home equipment, dance participation
Number of subjects: 76
Study 22025143 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (intermittent: 1,000 mg/m² twice daily for 14 of every 21 days; n = 107)
Number of subjects: 323
Study 22025143 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (continuous: 650 mg/m² twice daily for 21 of every 21 days; n = 107)
Number of subjects: 323
Study 22025143 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (both intermittent and continuous combined)
Number of subjects: 323
Study 22025143 — intervention group
Group type: COMPARATOR
Intervention: CMF (oral cyclophosphamide 100 mg/m² days 1 to 14, intravenous methotrexate 40 mg/m² and fluorouracil 600 mg/m² on days 1 and 8 every 28 days; n = 109)
Number of subjects: 323
Study 18420749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg)
Number of subjects: 88
Study 18420749 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 88
Study 16445968 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II RH
Number of subjects: 110
Study 16445968 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III Nerve-sparing RH (NSRH)
Number of subjects: 110
Study 16445968 — intervention group
Group type: COMPARATOR
Intervention: Type III RH
Number of subjects: 110
Study 12919004 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe interval-training programs (4- and 8-week duration) in few-trained subjects
Number of subjects: 13
Study 12919004 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe interval-training programs (4- and 8-week duration) in well-trained subjects
Number of subjects: 13
Study 11105539 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% cream (regimen A)
Number of subjects: 124
Study 11105539 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutrimazole 2% cream (regimen B)
Number of subjects: 124
Study 11105539 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutrimazole 4% cream (regimen C)
Number of subjects: 124
Study 11105539 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (regimen D)
Number of subjects: 124
Study 8600432 — intervention group
Group type: EXPERIMENTAL
Intervention: Central retinal artery (CRA) blood flow velocity measurement using pulsed Doppler sonography
Number of subjects: 85
Study 8600432 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal microcirculation (flow omega-ret) measurement
Number of subjects: 85
Study 8600432 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistivity index (RI) as a marker of vessel rigidity
Number of subjects: 85
Study 8600432 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve head blood flow measurement
Number of subjects: 85
Study 1404440 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint format
Number of subjects: 135
Study 1404440 — intervention group
Group type: EXPERIMENTAL
Intervention: Group format
Number of subjects: 135
Study 1404440 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual format
Number of subjects: 135
Study 1404440 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-oriented information
Number of subjects: 135
Study 3890519 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with 10% sulfacetamide sodium ophthalmic solution
Number of subjects: 51
Study 3890519 — intervention group
Group type: COMPARATOR
Intervention: Oral erythromycin estolate (50 mg/kg/day)
Number of subjects: 51
Study 29797676 — intervention group
Group type: EXPERIMENTAL
Intervention: BAS/TAC/EVR
Number of subjects: 273
Study 29797676 — intervention group
Group type: EXPERIMENTAL
Intervention: rAGT/TAC/EVR
Number of subjects: 273
Study 29797676 — intervention group
Group type: COMPARATOR
Intervention: BAS/TAC/MPS
Number of subjects: 273
Study 27565717 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder messages (monthly)
Number of subjects: 48
Study 27565717 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 48
Study 25438908 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 13032
Study 25438908 — intervention group
Group type: COMPARATOR
Intervention: No Anemia
Number of subjects: 13032
Study 23409591 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation exercise intervention (3 times per week for 8 weeks prior to surgery)
Number of subjects: 18
Study 23409591 — intervention group
Group type: COMPARATOR
Intervention: Usual preoperative care prescribed by the physician (Control)
Number of subjects: 18
Study 20975053 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 μg/min human αCGRP infusion
Number of subjects: 18
Study 20975053 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan subcutaneous injection
Number of subjects: 18
Study 20975053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 18
Study 18550577 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 627
Study 18550577 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX-4
Number of subjects: 627
Study 16507381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir oral suspension
Number of subjects: 965
Study 16507381 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate potassium, cefprozil, azithromycin, or generic amoxicillin
Number of subjects: 965
Study 11986112 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Scale (CES-D)
Number of subjects: 298
Study 11986112 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite International Diagnostic Interview, Short Form (CIDI-SF)
Number of subjects: 298
Study 11986112 — intervention group
Group type: COMPARATOR
Intervention: N/A (control group)
Number of subjects: 298
Study 11127759 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens (0.3 mg, 0.625 mg, or 1.25 mg)
Number of subjects: 406
Study 11127759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 8761904 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical computed tomography (CT)
Number of subjects: 50
Study 8761904 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (control)
Number of subjects: 50
Study 1552456 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous free gingival graft (FGG)
Number of subjects: 8
Study 1552456 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐stage coronally‐positioned flap (CPF)
Number of subjects: 8
Study 3698460 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg lorazepam
Number of subjects: 7
Study 3698460 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg lorazepam
Number of subjects: 7
Study 3698460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29277822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks) and cyclophosphamide (150-250 mg/m2) added to a combination of gemcitabine, fluorouracil, leucovorin, irinotecan and a platinum analogue.
Number of subjects: 9
Study 24055782 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfused with saline to replace 100% of fluid losses (0% hypohydrated)
Number of subjects: 10
Study 24055782 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfused with saline to replace 33% of fluid losses (-2% hypohydrated)
Number of subjects: 10
Study 24055782 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfused with saline to replace 0% of fluid losses (-3% hypohydrated)
Number of subjects: 10
Study 23760808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine local analgesia
Number of subjects: 80
Study 23760808 — intervention group
Group type: COMPARATOR
Intervention: No lidocaine local analgesia (Control)
Number of subjects: 80
Study 20053142 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 64
Study 19134276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow mononuclear cells (BM‐MNCs) transplantation
Number of subjects: 258
Study 19134276 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 258
Study 16140397 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine followed by a 23-valent pneumococcal polysaccharide booster
Number of subjects: 74
Study 16140397 — intervention group
Group type: COMPARATOR
Intervention: Control hepatitis A vaccine
Number of subjects: 74
Study 12499347 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (ferrous sulfate 60 mg Fe once daily for 8 weeks)
Number of subjects: 363
Study 12499347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 10577432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramped Bruce protocol
Number of subjects: 23
Study 10577432 — intervention group
Group type: COMPARATOR
Intervention: Bruce protocol
Number of subjects: 23
Study 7555975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) HCl, single doses of 2-24 mg
Number of subjects: 58
Study 7555975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) HCl, daily doses of 2-10 mg for 5 days
Number of subjects: 58
Study 7555975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) HCl, daily doses of 6 or 12 mg for 14 days
Number of subjects: 58
Study 7555975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) HCl
Number of subjects: 58
Study 1940122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (40 to 80 mg/kg/day)
Number of subjects: 66
Study 1940122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (higher than 100 mg/kg/day)
Number of subjects: 66
Study 1940122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (monotherapy)
Number of subjects: 66
Study 1940122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (dose reduction due to hyperkinesia)
Number of subjects: 66
Study 1940122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 66
Study 7453240 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intra-aortic balloon catheter (central-lumen balloon)
Number of subjects: 18
Study 7453240 — intervention group
Group type: COMPARATOR
Intervention: Standard intra-aortic balloon catheter (control group)
Number of subjects: 18
Study 30135024 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT + SWO
Number of subjects: 10
Study 30135024 — intervention group
Group type: COMPARATOR
Intervention: cVMAT
Number of subjects: 10
Study 30135024 — intervention group
Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 10
Study 27888542 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) piperacillin/tazobactam (4-hour infusion)
Number of subjects: 367
Study 27888542 — intervention group
Group type: COMPARATOR
Intervention: Non-extended infusion (NEI) piperacillin/tazobactam (30-minute infusion)
Number of subjects: 367
Study 27888542 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) piperacillin/tazobactam
Number of subjects: 367
Study 27888542 — intervention group
Group type: COMPARATOR
Intervention: Non-extended infusion (NEI) piperacillin/tazobactam
Number of subjects: 367
Study 27888542 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) piperacillin/tazobactam (post hoc analysis)
Number of subjects: 367
Study 27888542 — intervention group
Group type: COMPARATOR
Intervention: Non-extended infusion (NEI) piperacillin/tazobactam (post hoc analysis)
Number of subjects: 367
Study 26353825 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-V (Video-feedback Intervention to promote Positive Parenting) in combination with care-as-usual
Number of subjects: 100
Study 26353825 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 100
Study 23531117 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg drospirenone/0.5 mg 17β-estradiol (DRSP/E2)
Number of subjects: 662
Study 23531117 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg norethisterone acetate (NETA)/1.0 mg E2
Number of subjects: 662
Study 21505096 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. 1.2 μg/kg Q4W
Number of subjects: 0
Study 21505096 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa QW/Q2W
Number of subjects: 0
Study 19767815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0% glucose solution
Number of subjects: 9
Study 19767815 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% glucose solution
Number of subjects: 9
Study 19767815 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose solution
Number of subjects: 9
Study 19767815 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic carbohydrate-electrolyte solutions
Number of subjects: 9
Study 18204744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized grass/rye mix extract (300 IR/daily)
Number of subjects: 105
Study 18204744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized grass/rye mix extract
Number of subjects: 105
Study 18204744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 15274236 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat tibial component with retention of the posterior cruciate ligament
Number of subjects: 20
Study 15274236 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave tibial component with retention of the posterior cruciate ligament
Number of subjects: 20
Study 15274236 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave tibial component with resection of the posterior cruciate ligament
Number of subjects: 20
Study 15274236 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized tibial component with resection of the posterior cruciate ligament
Number of subjects: 20
Study 15274236 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 controls)
Number of subjects: 20
Study 11704469 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (nutrition education) for premenopausal women (n = 174)
Number of subjects: 277
Study 11704469 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 103)
Number of subjects: 277
Study 9744123 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-part, individually tailored smoking cessation program
Number of subjects: 300
Study 9744123 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 8545714 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft plus demineralized bone matrix
Number of subjects: 77
Study 8545714 — intervention group
Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 77
Study 8545714 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 77
Study 8545714 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 77
Study 2614056 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel closed needle-sampling system (Lab-Site, Migada Ltd)
Number of subjects: 0
Study 2614056 — intervention group
Group type: COMPARATOR
Intervention: Stopcock system
Number of subjects: 0
Study 305734 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) and pethidine as necessary
Number of subjects: 40
Study 305734 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine (30 mg) alone
Number of subjects: 40
Study 31863561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of autologous bone marrow-derived mesenchymal stromal cells (MSCs)
Number of subjects: 60
Study 31863561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31779711 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus levofloxacin (4.5 million unit loading dose followed by 3 million units every 8 h, levofloxacin 500 mg every 12 h)
Number of subjects: 232
Study 31779711 — intervention group
Group type: COMPARATOR
Intervention: Meropenem plus levofloxacin (2 g every 8 h, levofloxacin 500 mg every 12 h)
Number of subjects: 232
Study 31779711 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus levofloxacin
Number of subjects: 232
Study 31779711 — intervention group
Group type: COMPARATOR
Intervention: Meropenem plus levofloxacin
Number of subjects: 232
Study 28390688 — intervention group
Group type: EXPERIMENTAL
Intervention: D&C plus ACP gel
Number of subjects: 152
Study 28390688 — intervention group
Group type: COMPARATOR
Intervention: D&C alone
Number of subjects: 152
Study 26414481 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased SNAP benefits (13.6% increase of the maximum allotment, equivalent to $24 to $144 for one-to-eight person households)
Number of subjects: 0
Study 26414481 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased SNAP benefits (13.6% increase of the maximum allotment)
Number of subjects: 0
Study 25270176 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician Asthma Care Education program (2 interactive seminar sessions of 2.5 hours each)
Number of subjects: 870
Study 25270176 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician Asthma Care Education program
Number of subjects: 870
Study 22795579 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulvectomy and inguinofemoral lymphadenectomy
Number of subjects: 28
Study 22795579 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy, age-matched women)
Number of subjects: 28
Study 19318667 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.005 mg/kg; n = 336)
Number of subjects: 1000
Study 19318667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg; n = 339)
Number of subjects: 1000
Study 19318667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine and Glycopyrrolate
Number of subjects: 1000
Study 19318667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL of normal saline solution; n = 325)
Number of subjects: 1000
Study 17697245 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil system
Number of subjects: 45
Study 17697245 — intervention group
Group type: COMPARATOR
Intervention: System B
Number of subjects: 45
Study 17697245 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation
Number of subjects: 45
Study 15014015 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TEM) administered orally daily on days 1-5 and BCNU administered intravenously either on day 1 before TEM (Seq B‐‐>T) or day 5 after TEM (Seq T‐‐>B).
Number of subjects: 63
Study 15014015 — intervention group
Group type: COMPARATOR
Intervention: Seq T‐‐>B (BCNU on day 5 after TEM)
Number of subjects: 63
Study 15014015 — intervention group
Group type: COMPARATOR
Intervention: Seq B‐‐>T (BCNU on day 1 before TEM)
Number of subjects: 63
Study 15014015 — intervention group
Group type: EXPERIMENTAL
Intervention: AGAT activity in PBMCs
Number of subjects: 63
Study 11200353 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced moving-table MR angiography
Number of subjects: 13
Study 10450426 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 122
Study 7853071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics education program (pilot program in 1988 and full program from 1989 to 1991)
Number of subjects: 152
Study 2755859 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine (MS Contin, Purdue Frederick Co.)
Number of subjects: 83
Study 2755859 — intervention group
Group type: COMPARATOR
Intervention: Short-acting analgesia
Number of subjects: 83
Study 4837057 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (3 months, 3 sessions per week, cycling on an ergometer bicycle)
Number of subjects: 63
Study 4837057 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no physical training)
Number of subjects: 63
Study 4837057 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 63
Study 4837057 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 63
Study 31479790 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdural drain (SDD)
Number of subjects: 220
Study 31479790 — intervention group
Group type: COMPARATOR
Intervention: Subperiosteal drain (SPD)
Number of subjects: 220
Study 28492195 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide-60% oxygen
Number of subjects: 60
Study 28492195 — intervention group
Group type: COMPARATOR
Intervention: Triclofos sodium (70 mg/kg body weight)
Number of subjects: 60
Study 28492195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nitrous oxide-oxygen and triclofos sodium
Number of subjects: 60
Study 28492195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral route of administration
Number of subjects: 60